StockMarketWire.com - Hikma Pharmaceuticals and partner Civica said they would imminently begin shipping heparin sodium injections and seven other essential injectable medicines in the US.

The move came as the industry worked to avoid a shortage of heparin, which was commonly prescribed for patients with significant blood clots in their lungs or clogged arteries.

It was also prescribed to patients receiving dialysis, or undergoing major orthopedic and cardiac surgery.

Shortages of heparin, which is derived from porcine intestinal mucosa, may be possible due to an outbreak of African Swine Fever that has killed many of the world's pigs, the companies said.

The other seven shortage medications that would be shipped by the end of the year included naloxone hydrochloride injections, for the treatment of opioid abuse, and dexamethasone injections that treat a range of conditions, including allergic reactions and breathing problems.


At 1:13pm: [LON:HIK] Hikma Pharmaceuticals PLC share price was -5p at 1904p



Story provided by StockMarketWire.com